Results 1 to 10 of about 27,165 (239)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate. [PDF]

Drugs R D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Murrell DE, Kennard BC, Bertoni ME, Cluck DB, Moorman JP, Brown SD, Wang K, Duffourc MM, Harirforoosh S.   +8 more
europepmc   +3 more sources

Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. [PDF]

J Gastroenterol Hepatol
Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD ...
Ogawa E, Kohjima M, Koyanagi T, Dohmen K, Ooho A, Kawano A, Furusyo N, Kajiwara E, Satoh T, Takahashi K, Azuma K, Sugimoto R, Ichiki Y, Senju T, Amagase H, Tanaka M, Nakamuta M, Nomura H, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.   +19 more
europepmc   +2 more sources

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis

Journal of the International AIDS Society
Introduction Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir.
Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim   +4 more
doaj   +2 more sources

Comparative analysis of tenofovir alafenamide and entecavir on renal function and serum lipids in liver transplant recipients: a controlled retrospective cohort study. [PDF]

BMC Gastroenterol
Background Antiviral treatments can impact serum lipids as well as kidney function. We conducted a retrospective observational study with a 48-month follow-up period, involving liver transplant recipients receiving either entecavir or tenofovir ...
Döngelli H, Danış N, Ünek T, Egeli T, Ağalar C, Özbilgin M, Ellidokuz H, Akarsu M.   +7 more
europepmc   +2 more sources

A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS). [PDF]

PLoS One
Objects Tenofovir Alafenamide (TAF) is a novel antiviral drug approved for the treatment of hepatitis B virus (HBV) infection. Our research objective was to evaluate the safety characteristics of TAF in practical settings by analyzing data from the FDA ...
Zhang C, Wen J, Li Y.
europepmc   +2 more sources

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials [PDF]

Lancet, The, 2015
none27siBackground Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir
Paul E Sax, Michael T Yin, Fa Post
exaly   +3 more sources

Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe. [PDF]

HIV Med
To compare BMI‐for‐age z‐score (zBMI) changes in treatment‐experienced children and young people living with HIV aged 6 to
European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group.
europepmc   +2 more sources

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan. [PDF]

MDM Policy Pract
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Tan EC, Yehoshua A, Jeyakumar S, Peng P, Lin A, Smith NJ, Kachru N.   +6 more
europepmc   +2 more sources

Tenofovir alafenamide fumarate

Antiviral Therapy, 2022
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV.
William A Lee, Andrew K Cheng
openaire   +2 more sources

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study

Frontiers in Pharmacology, 2023
Background/aim: Tenofovir amibufenamide (TMF) has shown potent antiviral efficacy in randomized clinical studies. This study aimed to reveal the effectiveness and safety of tenofovir amibufenamide in the real world and compared tenofovir amibufenamide to
Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen   +7 more
doaj   +1 more source